Spanish Lung Cancer Group
Published: 3 Dec 2008
Views: 15620
Prof. Rafael Rosel
Benefits of customising erlotinib therapy for NSCLC.
- Categories:
- Lung & pleura
Related Videos
SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-sma...
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
Sotorasib for advanced non-small cell lung cancer
Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France
6 Nov 2020
Adagrasib in advanced/metastatic NSCLC with KRAS G12C mutation
Dr Pasi Janne - Dana Farber Cancer Institute, Boston, USA
4 Nov 2020
OncoAlert and ecancer weekly roundup for October 26 - 31, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
2 Nov 2020
Updates in geriatric medical oncology from SIOG meeting
Dr Enrique Soto - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zu...
28 Oct 2020
OncoAlert and ecancer weekly roundup for September 20 - 26, 2020
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
28 Sep 2020
Exon 20 insertions in NSCLC - ESMO 2020
Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro
25 Sep 2020
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer p...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
23 Sep 2020
